PeptidePros
All Peptides

LL-37

Also known as: Human cathelicidin peptide, CAMP

Evidence Tier B-Chigh riskintermediatenot approved

Human antimicrobial peptide with topical wound healing studies. Antimicrobial therapeutic claims trigger regulatory scrutiny.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

Overview

LL-37 is a human cathelicidin peptide with antimicrobial and immunomodulatory properties. Human topical studies in chronic leg ulcers report safety/tolerability and effects on healing predictors at lower doses. Topical use appears tolerable in trials; systemic use is a different risk profile. Marketing with antimicrobial therapeutic claims triggers high regulatory scrutiny.

Research Details

Mechanism of Action

Antimicrobial and immunomodulatory; host defense and inflammation modulation.

Study Dose Range

Human topical studies in wound healing contexts.

Administration Routes

topical

Onset / Timeline

Wound endpoints measured over weeks.

Expected Effects

Wound healing support; antimicrobial properties in topical application.

Adverse Effects

Topical appears tolerable; systemic use carries different risk profile.

Contraindications

No formal label.

Interaction Notes

Unknown.

Related Goals
Tissue Repair & RecoveryImmune SupportSkin & Hair
Available From

No vendors currently listed for this peptide.

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.